Initial Statement of Beneficial Ownership (3)

FORM 3	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES	OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response... 0.5
	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person ^*

Johnson Shane Aaron

2. Date of Event Requiring Statement (MM/DD/YYYY) 11/2/2021

3. Issuer Name and Ticker or Trading Symbol

InMed Pharmaceuticals Inc. [INM]

(Last) (First) (Middle)

C/O INMED PHARMACEUTICALS INC., 310-815 WEST HASTINGS ST.

4. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director _____ 10% Owner
___X___ Officer (give title below) _____ Other (specify below)
SVP & GM of BayMedica LLC /

(Street)

VANCOUVER, A1 V6C1B4

(City) (State) (Zip)

5. If Amendment, Date Original Filed(MM/DD/YYYY)

6. Individual or Joint/Group Filing(Check Applicable Line)

_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	4574	D
Common Stock	278428	I	By Shane A. Johnson TTEE of the Shane A. Johnson Trust DTD April 18, 1997, as amended

*Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)*
1. Title of Derivate Security (Instr. 4)	2. Date Exercisable and Expiration Date (MM/DD/YYYY)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivate Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security		6. Nature of Indirect Beneficial Ownership (Instr. 5)
Employee Stock Option (Right to Buy)	⁽¹⁾	10/17/2026	Common shares	60000	$1.40	D
Employee Stock Option (Right to Buy)	⁽²⁾	10/17/2026	Common shares	35000	$1.40	D

Explanation of Responses:
(1)	The options were granted on 10/18/2021 and will vest as follows: 25% of stock options will vest 6 months after the date of Grant; 25% of stock options will vest 12 months after the date of the Grant; 25% stock options will vest 18 months after the date of the Grant; and 25% stock options will vest 24 months after the date of the Grant.
(2)	Complete vesting shall occur on the one year anniversary of the grant date (October 18, 2022).

Remarks:
Exhibit 24 - Power of Attorney

Reporting Owners
Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
Johnson Shane Aaron C/O INMED PHARMACEUTICALS INC. 310-815 WEST HASTINGS ST. VANCOUVER, A1 V6C1B4			SVP & GM of BayMedica LLC